Figure EV3. The effect of the PPARG agonist rosiglitazone on the growth of UMB, SV7, and T5‐Xn cells.

The three cell types were treated with either rosiglitazone (ROSI) or vehicle (CNT) and assessed for relative growth ratio following 48 h. Results shown as mean ± SD (n = 3). **P < 0.01 (one‐way ANOVA with Bonferroni post hoc test). The exact P‐values are specified in Appendix Table S5.